Patritumab
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].
Product Specifications
CAS Number
[1262787-83-6]
Product Name Alternative
Human Anti-ERBB3 Recombinant Antibody
UNSPSC
12352203
Target
Akt; EGFR; ERK; PARP; Survivin
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/patritumab.html
Purity
99.28
Solubility
10 mM in DMSO
Smiles
[Patritumab]
Molecular Weight
(146.86 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99275/Patritumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99275/Patritumab-SDS-MedChemExpress.pdf
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
